Relmada Therapeutics's total assets for Q3 2024 were $55.72M, a decrease of -21.55% from the previous quarter. RLMD total liabilities were $8.10M for the fiscal quarter, a -15.07% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.